CD8A and pneumonia: It has a therapeutic impact on pneumonia model rats by reducing B lymphocytes, CD8+ ratio, and elevated levels of IL-1α, IL-1β, IL-2, IL-10, TNF-α, IFN-α, IFN-γ, IgM, IgG, CD4+/CD8+, and NK cells (122).